EXCEED THE SPACE PROVIDED. Retinal neovascularization is associated with proliferative diabetic retinopathy and retinopathy of prematurity. Clinical studies suggest that insulin like growth factor-1 (IGF-1) is involved in both diseases and has direct effects on retinal vasculature. To understand the mechanisms by which IGF-1 contributes to normal and abnormal vascular physiology, several processes must be understood in greater detail. This includes how IGF-1 receptor (IGF-1R) expression affects booth normal and abnormal retinal vascular growth and how expression of IGF binding protein-3 (IGFBP-3) mediates IGF-1 bioavailability and influences endothelial cell behavior. Of the seven known IGFBPs, IGFBP-3 is the primary carrier of IGF-1 in the serum and its direct apoptotic effects has been demonstrated in numerous cells systems including tumor cells. These apoptotic effects of IGFBP-3 are independent of its ability to bind IGF-1. This proposal focuses on manipulating IGF- 1R and IGFBP-3 expression to examine their effects on aberrant vascularization of the retina. We will test the following hypothesis: Decreasing the expression of IGF-1R and increasing the secretion of soluble IGFBP-3 will result in the inhibition of retinal neovascularization though the induction of endothelial cell apoptosis.
In Aim 1, we will synthesize IGF-1R mRNA-specific hammerhead ribozymes, infect human retinal endothelial cells with these ribozymes, and characterize ribozyme effects on IGF-1R expression. We will characterize the apoptotic pathways activated by IGFBP-3 and evaluate the action of endogenously produced IGFBP3 (to induce apoptosis directly) in HREC; the effects of the combined effect of The IGF-1R inhibition with overexpression of IGFBP-3 on HREC apoptosis will also be examined.
In Aim 2, we will package our IGF-1R ribozyme into adeno-associated virus (AAV) for site directed expression. A cell cycle/proliferating endothelial cell-specific promoter will drive expression of the IGF-1R ribozymes. These AAV-packaged constructs will be used to inhibit retinal and pre-retinal neovascularization specifically in two mouse models: the mouse pup model of oxygen-induced retinopathy and an adult mouse model that we have developed.
In Aim 3, we will express IGFBP-3 using a rAAV protein expression vector and test it in the two mouse models described in Aim 2. We will combine the AAV-IGF-1R ribozymes with AAV-IGFBP-3 to determine if additional inhibition of proliferation and apoptosis occurs. Targeting the IGF-IR and IGFBP-3 in this manner will provide a tool for understanding the role of the IGF-1 system in retinal vascular growth and may provide novel way to inhibit retinal angiogenesis. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY007739-15
Application #
6843137
Study Section
Special Emphasis Panel (ZRG1-VISC (01))
Program Officer
Dudley, Peter A
Project Start
1989-08-01
Project End
2006-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
15
Fiscal Year
2005
Total Cost
$327,375
Indirect Cost
Name
University of Florida
Department
Pharmacology
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Shaw, Lynn Calvin; Li Calzi, Sergio; Li, Nan et al. (2018) Enteral Arg-Gln Dipeptide Administration Increases Retinal Docosahexaenoic Acid and Neuroprotectin D1 in a Murine Model of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci 59:858-869
Coughlin, Brandon A; Feenstra, Derrick J; Mohr, Susanne (2017) Müller cells and diabetic retinopathy. Vision Res 139:93-100
Yan, Yuanqing; Gao, Ruli; Trinh, Thao L P et al. (2017) Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics. Clin Cancer Res 23:6363-6373
Bhatwadekar, Ashay D; Beli, Eleni; Diao, Yanpeng et al. (2017) Conditional Deletion of Bmal1 Accentuates Microvascular and Macrovascular Injury. Am J Pathol 187:1426-1435
Caballero, Sergio; Kent, David L; Sengupta, Nilanjana et al. (2017) Bone Marrow-Derived Cell Recruitment to the Neurosensory Retina and Retinal Pigment Epithelial Cell Layer Following Subthreshold Retinal Phototherapy. Invest Ophthalmol Vis Sci 58:5164-5176
Bhatwadekar, Ashay D; Duan, Yaqian; Korah, Maria et al. (2017) Hematopoietic stem/progenitor involvement in retinal microvascular repair during diabetes: Implications for bone marrow rejuvenation. Vision Res 139:211-220
Basavarajappa, Halesha D; Sulaiman, Rania S; Qi, Xiaoping et al. (2017) Ferrochelatase is a therapeutic target for ocular neovascularization. EMBO Mol Med 9:786-801
Salazar, Tatiana E; Richardson, Matthew R; Beli, Eleni et al. (2017) Electroacupuncture Promotes Central Nervous System-Dependent Release of Mesenchymal Stem Cells. Stem Cells 35:1303-1315
Hu, Ping; Hunt, Nicholas H; Arfuso, Frank et al. (2017) Increased Indoleamine 2,3-Dioxygenase and Quinolinic Acid Expression in Microglia and Müller Cells of Diabetic Human and Rodent Retina. Invest Ophthalmol Vis Sci 58:5043-5055
Song, Chunjuan; Mitter, Sayak K; Qi, Xiaoping et al. (2017) Oxidative stress-mediated NF?B phosphorylation upregulates p62/SQSTM1 and promotes retinal pigmented epithelial cell survival through increased autophagy. PLoS One 12:e0171940

Showing the most recent 10 out of 93 publications